ARQT

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium

Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation